Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8474 USD | +2.10% | +2.34% | +14.51% |
May. 03 | Transcript : Rapid Micro Biosystems, Inc., Q1 2024 Earnings Call, May 03, 2024 | |
May. 03 | Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q1 Revenue $5.6M | MT |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.51% | 35.58M | C- | ||
+37.78% | 705B | C+ | ||
+32.82% | 583B | B | ||
-3.51% | 364B | C+ | ||
+19.94% | 332B | B- | ||
+5.14% | 291B | C+ | ||
+16.64% | 238B | B+ | ||
-4.13% | 210B | A+ | ||
+10.63% | 209B | B- | ||
+9.32% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RPID Stock
- Ratings Rapid Micro Biosystems, Inc.